Table 1. Baseline Demographic and Clinical Characteristics.
| Characteristic | No. (%)a | |
|---|---|---|
| Trastuzumab for 9 wk (n = 1085) |
Trastuzumab for 51 wk (n = 1089) |
|
| Age, median (IQR), y | 56 (49-64) | 56 (48-63) |
| Weight, median (IQR), kg | 70 (62-80) | 70 (61-79) |
| Race | ||
| White | 1061 (98) | 1066 (98) |
| Other | 24 (2) | 23 (2) |
| Menopausal status | ||
| Premenopausal | 353 (33) | 364 (33) |
| Postmenopausal | 731 (67) | 724 (66) |
| Not available | 1 (<1) | 1 (<1) |
| World Health Organization performance status | ||
| 0 | 975 (90) | 963 (88) |
| 1 | 102 (9) | 112 (10) |
| Not available | 8 (1) | 14 (1) |
| Breast tumor diameter, mm | ||
| ≤10 | 129 (12) | 155 (14) |
| 11-20 | 473 (44) | 453 (42) |
| 21-50 | 447 (41) | 452 (42) |
| >50 | 36 (3) | 29 (3) |
| No. of axillary lymph nodes with cancer | ||
| 0 | 647 (60) | 649 (60) |
| 1-3 | 322 (30) | 320 (29) |
| >3 | 116 (11) | 120 (11) |
| Stage | ||
| I | 427 (39) | 430 (39) |
| II | 529 (49) | 528 (48) |
| III | 129 (12) | 131 (12) |
| Histological grade | ||
| 1 | 26 (2) | 27 (2) |
| 2 | 340 (31) | 327 (30) |
| 3 | 714 (66) | 731 (67) |
| Not available | 5 (<1) | 4 (<1) |
| Histological type | ||
| Ductal | 1000 (92) | 1000 (92) |
| Lobular | 44 (4) | 49 (4) |
| Other | 39 (4) | 39 (4) |
| Not available | 2 (<1) | 1 (<1) |
| Estrogen receptor status | ||
| Positive | 711 (66) | 723 (66) |
| Negative | 374 (34) | 366 (34) |
| Progesterone receptor status | ||
| Positive | 504 (46) | 517 (47) |
| Negative | 576 (53) | 565 (52) |
| Not available | 5 (<1) | 7 (1) |
| HER2 status | ||
| Positive | 1078 (99) | 1084 (100) |
| Negative | 0 | 1 (<1) |
| Unconfirmed, IHC++ | 7 (1) | 4 (1) |
Abbreviations: HER2, human epidermal growth factor-2; IHC, immunohistochemistry; IQR, interquartile range.
a
Percentages may not total 100 because of rounding.